Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended	12 Months Ended
	Aug. 22, 2017	Jul. 31, 2017	Jan. 16, 2017	Nov. 16, 2012	Jul. 31, 2012	Jul. 31, 2018	Jul. 31, 2011
Commitments and Contingencies	The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing form Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.  Generex management believes the Pharma Trials, LLC Financing was not subject to the prohibitions because the representative of Pharma Trials, LLC was a director of Generex, and for other reasons.
Rental payments, current year						$ 92,430
Rental Payment, 2020						82,469
Rental payment, 2021						$ 9,306
Damages for Unpaid Invoices
Value of damages sought					$ 429,000
Lawsuit filing date					31-Dec-11
Name of Plaintiff					Vendor
Settlement of litigation				$ 125,000
Interest per annum, failure to pay settlement					3.00%
Fixed cost per annum, failure to pay settlement					$ 25,000
Breach of contract and detinue
Counterclaim proceeding							$ 200,000
Emmaus
Consideration to acquire controlling interest of capital stock			$ 225,000,000
Cash
Consideration to acquire controlling interest of capital stock			10,000,000
Shares
Consideration to acquire controlling interest of capital stock			$ 215,000,000
Deposit
Payment to Emmaus		$ 4,000,000